Lp-PLA2-IN-3
Modify Date: 2025-08-27 15:51:09
Lp-PLA2-IN-3 structure
|
Common Name | Lp-PLA2-IN-3 | ||
|---|---|---|---|---|
| CAS Number | 2196245-16-4 | Molecular Weight | 467.85 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H13ClF3N3O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Lp-PLA2-IN-3Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2)[1]. |
| Name | Lp-PLA2-IN-3 |
|---|
| Description | Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2)[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours and 35.5%, respectively[1]. Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively[1]. Animal Model: Male Sprague−Dawley (SD) rats (180-220 g)[1] Dosage: 3 mg/kg Administration: p.o. (Pharmacokinetic Analysis) Result: The Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 6.2 μg h/mL, 7.7 hours and 35.5%, respectively. |
| References |
| Molecular Formula | C20H13ClF3N3O3S |
|---|---|
| Molecular Weight | 467.85 |